嵌合抗原受体
免疫疗法
神经科学
生物
计算生物学
生物信息学
医学
免疫学
免疫系统
作者
Rebecca C. Larson,Marcela V. Maus
出处
期刊:Nature Reviews Cancer
[Springer Nature]
日期:2021-01-22
卷期号:21 (3): 145-161
被引量:556
标识
DOI:10.1038/s41568-020-00323-z
摘要
This Review discusses the major advances and changes made over the past 3 years to our understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the field has gained insight into how various molecular modules of the CAR influence signalling and function. We report on mechanisms of toxicity and resistance as well as novel engineering and pharmaceutical interventions to overcome these challenges. Looking forward, we discuss new targets and indications for CAR T cell therapy expected to reach the clinic in the next 1–2 years. We also consider some new studies that have implications for the future of CAR T cell therapies, including changes to manufacturing, allogeneic products and drug-regulatable CAR T cells. This Review outlines the major advances that have been made to the efficacy and safety of chimeric antigen receptor (CAR) T cell therapies over the past 3 years and looks to new findings that will have consequences for the future of this immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI